Angiodynamics (ANGO) 18.65 $ANGO
Angiodynamics Has Returned 23.4% Since SmarTrend Recommendation (ANGO)
Comtex SmarTrend(R) - Wed Feb 18, 11:14AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 4 months, Angiodynamics has returned 23.40% as of today's recent price of $18.80.
ANGO: 18.65 (+0.12)
Shares of ANGO Up 19.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 11, 10:00AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 4 months, Angiodynamics has returned 19.20% as of today's recent price of $18.16.
ANGO: 18.65 (+0.12)
Uptrend Call Working As Angiodynamics Stock Rises 21.8% (ANGO)
Comtex SmarTrend(R) - Wed Feb 04, 9:24AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 4 months, Angiodynamics has returned 21.82% as of today's recent price of $18.56.
ANGO: 18.65 (+0.12)
AngioDynamics Celerity System Gets Expanded FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:00PM CST
Per the latest approval, clinicians can do away with the follow-up X-ray when AngioDynamics Inc.'s (ANGO) Celerity system is used to assist in the positioning of PICCs in adult patients.
ABMD: 60.00 (-1.10), INGN: 32.05 (-0.10), ANGO: 18.65 (+0.12), SURG: 5.21 (-0.02)
AngioDynamics Receives Expanded "No Chest X-Ray" FDA Clearance for Celerity Tip Location System
GlobeNewswire - Thu Jan 29, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for the Celerity tip location system.
ANGO: 18.65 (+0.12)
22.0% Return Seen to Date on SmarTrend Angiodynamics Call (ANGO)
Comtex SmarTrend(R) - Tue Jan 20, 11:15AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 3 months, Angiodynamics has returned 22.02% as of today's recent price of $18.59.
ANGO: 18.65 (+0.12)
AngioDynamics Still Looking For Inflection
Stephen Simpson, CFA - at Seeking Alpha - Sat Jan 10, 11:59AM CST
BCR: 171.48 (+0.79), TFX: 119.98 (+0.07), ANGO: 18.65 (+0.12)
AngioDynamics Beats Q2 Earnings by a Penny, Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 8:10AM CST
AngioDynamics Inc. (ANGO) reported second-quarter 2015 earnings of 17 cents per share, which beat the Zacks Consensus Estimate by a penny
BSX: 17.84 (+0.03), BCR: 171.48 (+0.79), ANGO: 18.65 (+0.12), MMSI: 19.40 (-0.02)
AngioDynamics reports FQ2, ups earnings guidance
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 6:09AM CST
ANGO: 18.65 (+0.12)
uniQure Appoints Matthew Kapusta as Chief Financial Officer
GlobeNewswire - Fri Jan 09, 4:08AM CST
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Matthew Kapusta has joined uniQure's management team as Chief Financial Officer effective January 1, 2015. Mr. Kapusta brings to the Company nearly 20 years of life science industry experience from investment banking and finance, as well as corporate development positions. In addition, uniQure announced the following changes to its Supervisory Board: Francois Meyer, a member of the Supervisory Boards of uniQure and its predecessor company AMT since 2010, and Sander Slootweg, Managing Partner of Forbion Capital Partners and Supervisory Board Member from 2006 to 2008 and again starting in 2012, will step down from the Supervisory Board. Philip Astley-Sparke, who has overseen uniQure's U.S. operations over the past two years, will be nominated for appointment to the Supervisory Board and will pass his operational responsibilities to Mr. Kapusta, who will be based in uniQure's Massachusetts manufacturing facility. Additionally, Prof. Hugo Katus, who is recognized as one of the leading heart surgeons and clinicians worldwide, has agreed to be nominated for appointment to the Supervisory Board. These changes are intended to add relevant breadth of experience and independence to the uniQure Supervisory Board.
QURE: 27.27 (-0.28), ANGO: 18.65 (+0.12)
AngioDynamics' (ANGO) CEO Joe DeVivo on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 08, 10:28PM CST
ANGO: 18.65 (+0.12)
AngioDynamics (ANGO) Stock Climbs in After-Hours Trading Today Following Earnings Beat
at The Street - Thu Jan 08, 3:43PM CST
AngioDynamics (ANGO) shares are rising after the company beat analysts' second quarter earnings and revenue expectations.
ANGO: 18.65 (+0.12)
AngioDynamics (ANGO) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Jan 08, 3:25PM CST
ANGO: 18.65 (+0.12)
AngioDynamics Reports 2015 Second Quarter Financial Results
GlobeNewswire - Thu Jan 08, 3:06PM CST
-- Second Quarter Fiscal 2015 Net Sales increased 4% to $92.1 million; 5% sales growth excluding supply agreement
ANGO: 18.65 (+0.12)
AngioDynamics beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 3:04PM CST
ANGO: 18.65 (+0.12)
Natus Medical Advances Newborn Care with Nicview Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 12:42PM CST
Natus Medical Inc (BABY) is presently focusing on enhancing its offerings for the newborn care market
JNJ: 102.40 (+0.71), ABMD: 60.00 (-1.10), BABY: 38.98 (+1.24), ANGO: 18.65 (+0.12)
IDEXX CAG, Global Growth Solid; Catalyst One in Focus in '15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 12:20PM CST
On Jan 7, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
HNSN: 0.70 (unch), EW: 146.77 (-2.17), IDXX: 152.80 (-1.65), ANGO: 18.65 (+0.12)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 4:35PM CST
HELE: 80.96 (+0.54), RT: 6.51 (+0.04), BBBY: 74.87 (-0.74), VOXX: 8.88 (+0.22), PSMT: 79.86 (+0.65), EOPN: 8.60 (unch), CUDA: 38.33 (-1.64), TCS: 18.81 (-0.62), ANGO: 18.65 (+0.12)
Angiodynamics Has Returned 23.4% Since SmarTrend Recommendation (ANGO)
Comtex SmarTrend(R) - Wed Feb 18, 11:14AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 4 months, Angiodynamics has returned 23.40% as of today's recent price of $18.80.
ANGO: 18.65 (+0.12)
Shares of ANGO Up 19.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 11, 10:00AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 4 months, Angiodynamics has returned 19.20% as of today's recent price of $18.16.
ANGO: 18.65 (+0.12)
Uptrend Call Working As Angiodynamics Stock Rises 21.8% (ANGO)
Comtex SmarTrend(R) - Wed Feb 04, 9:24AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 4 months, Angiodynamics has returned 21.82% as of today's recent price of $18.56.
ANGO: 18.65 (+0.12)
AngioDynamics Celerity System Gets Expanded FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:00PM CST
Per the latest approval, clinicians can do away with the follow-up X-ray when AngioDynamics Inc.'s (ANGO) Celerity system is used to assist in the positioning of PICCs in adult patients.
ABMD: 60.00 (-1.10), INGN: 32.05 (-0.10), ANGO: 18.65 (+0.12), SURG: 5.21 (-0.02)
AngioDynamics Receives Expanded "No Chest X-Ray" FDA Clearance for Celerity Tip Location System
GlobeNewswire - Thu Jan 29, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for the Celerity tip location system.
ANGO: 18.65 (+0.12)
22.0% Return Seen to Date on SmarTrend Angiodynamics Call (ANGO)
Comtex SmarTrend(R) - Tue Jan 20, 11:15AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 3 months, Angiodynamics has returned 22.02% as of today's recent price of $18.59.
ANGO: 18.65 (+0.12)
AngioDynamics Still Looking For Inflection
Stephen Simpson, CFA - at Seeking Alpha - Sat Jan 10, 11:59AM CST
BCR: 171.48 (+0.79), TFX: 119.98 (+0.07), ANGO: 18.65 (+0.12)
AngioDynamics Beats Q2 Earnings by a Penny, Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 8:10AM CST
AngioDynamics Inc. (ANGO) reported second-quarter 2015 earnings of 17 cents per share, which beat the Zacks Consensus Estimate by a penny
BSX: 17.84 (+0.03), BCR: 171.48 (+0.79), ANGO: 18.65 (+0.12), MMSI: 19.40 (-0.02)
AngioDynamics reports FQ2, ups earnings guidance
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 6:09AM CST
ANGO: 18.65 (+0.12)
uniQure Appoints Matthew Kapusta as Chief Financial Officer
GlobeNewswire - Fri Jan 09, 4:08AM CST
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Matthew Kapusta has joined uniQure's management team as Chief Financial Officer effective January 1, 2015. Mr. Kapusta brings to the Company nearly 20 years of life science industry experience from investment banking and finance, as well as corporate development positions. In addition, uniQure announced the following changes to its Supervisory Board: Francois Meyer, a member of the Supervisory Boards of uniQure and its predecessor company AMT since 2010, and Sander Slootweg, Managing Partner of Forbion Capital Partners and Supervisory Board Member from 2006 to 2008 and again starting in 2012, will step down from the Supervisory Board. Philip Astley-Sparke, who has overseen uniQure's U.S. operations over the past two years, will be nominated for appointment to the Supervisory Board and will pass his operational responsibilities to Mr. Kapusta, who will be based in uniQure's Massachusetts manufacturing facility. Additionally, Prof. Hugo Katus, who is recognized as one of the leading heart surgeons and clinicians worldwide, has agreed to be nominated for appointment to the Supervisory Board. These changes are intended to add relevant breadth of experience and independence to the uniQure Supervisory Board.
QURE: 27.27 (-0.28), ANGO: 18.65 (+0.12)
AngioDynamics' (ANGO) CEO Joe DeVivo on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 08, 10:28PM CST
ANGO: 18.65 (+0.12)
AngioDynamics (ANGO) Stock Climbs in After-Hours Trading Today Following Earnings Beat
at The Street - Thu Jan 08, 3:43PM CST
AngioDynamics (ANGO) shares are rising after the company beat analysts' second quarter earnings and revenue expectations.
ANGO: 18.65 (+0.12)
AngioDynamics (ANGO) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Jan 08, 3:25PM CST
ANGO: 18.65 (+0.12)
AngioDynamics Reports 2015 Second Quarter Financial Results
GlobeNewswire - Thu Jan 08, 3:06PM CST
-- Second Quarter Fiscal 2015 Net Sales increased 4% to $92.1 million; 5% sales growth excluding supply agreement
ANGO: 18.65 (+0.12)
AngioDynamics beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 3:04PM CST
ANGO: 18.65 (+0.12)
Natus Medical Advances Newborn Care with Nicview Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 12:42PM CST
Natus Medical Inc (BABY) is presently focusing on enhancing its offerings for the newborn care market
JNJ: 102.40 (+0.71), ABMD: 60.00 (-1.10), BABY: 38.98 (+1.24), ANGO: 18.65 (+0.12)
IDEXX CAG, Global Growth Solid; Catalyst One in Focus in '15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 12:20PM CST
On Jan 7, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
HNSN: 0.70 (unch), EW: 146.77 (-2.17), IDXX: 152.80 (-1.65), ANGO: 18.65 (+0.12)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 4:35PM CST
HELE: 80.96 (+0.54), RT: 6.51 (+0.04), BBBY: 74.87 (-0.74), VOXX: 8.88 (+0.22), PSMT: 79.86 (+0.65), EOPN: 8.60 (unch), CUDA: 38.33 (-1.64), TCS: 18.81 (-0.62), ANGO: 18.65 (+0.12)
